- Targeting the high-risk renal failure market of over 13 million people
- Aiming to cultivate Japan as a Northeast Asian hub for AI-driven kidney regeneration

ROKIT Healthcare (KOSDAQ 376900, CEO Seokhwan You), an AI-driven hyper-personalized organ regeneration platform company, announced today that it has received a decision of patent registration in Japan for its core source technology related to kidney regeneration. This achievement establishes a significant bridgehead for the company to introduce its AI-driven kidney regeneration platform to Japan, one of the world's three largest markets for kidney failure.

Chronic Kidney Disease (CKD) is a massive global health challenge affecting approximately 800 million people. In Japan, it is estimated that over 13 million people—accounting for about 12-13% of the adult population—suffer from CKD. This equates to one in eight Japanese adults. With a rapidly aging population and rising cases of diabetes and hypertension, the number of patients is increasing swiftly, and dialysis treatment costs in Japan are among the highest in the world.

The patent decided for registration in Japan covers a "Composition for kidney treatment using the omentum, a medical kit comprising the same, and a kidney treatment patch comprising a cured product thereof."

This technology represents an integrated regeneration platform. It utilizes AI to analyze patient data—including blood, urine, medical imaging, and lifestyle metrics—to predict the risk of kidney function decline at an early stage. Subsequently, using a 3D bioprinter, autologous cells and bio-ink are used to fabricate micro-kidney tissues and regeneration patches. These patches are then transplanted via a minimally invasive procedure to delay the deterioration of kidney function or restore it.

By securing protection for the entire process—ranging from ▲AI-driven kidney function prediction to ▲5-year long-term monitoring and ▲personalized kidney regeneration procedures—under a single AI-driven kidney regeneration platform, ROKIT Healthcare intends to prevent imitation by latecomers in the Japanese market and build a robust long-term IP entry barrier.

The AI-driven kidney regeneration platform, which integrates "Prediction & Prevention – Regeneration – Monitoring," offers a new treatment pathway distinct from the traditional paradigm focused on one-off dialysis or surgery. Industry experts evaluate this structure as highly attractive to Japanese health authorities and insurers (both public and private).

"Japan is one of the nations entering a super-aged society at the fastest rate globally, with a very high burden of kidney disease," said a representative from ROKIT Healthcare. "Starting with this patent registration in Japan, we will promote joint research and pilot programs with Japanese university hospitals and major medical institutions to establish Japan as the Northeast Asian hub for AI-driven kidney regeneration."

The representative further emphasized, "Our goal is to present a completely new option—'Predict with AI, Regenerate with My Own Cells'—to countless renal failure patients who previously had no choice but dialysis or transplantation due to a lack of cures. Building on this foothold in Japan, we plan to expand our AI-driven kidney regeneration platform to Korea, the United States, and Europe."